NanoSyrinx
Discovery-stage synthetic biology company developing a genetically encoded delivery platform, derived from bacterial injection systems, to enable targeted intracellular (cytosolic) delivery of protein and peptide therapeutics. The company combines genetic engineering, microbial production and payload/targeting-domain design to produce self-assembling delivery vehicles for preclinical development.
Industries
Nr. of Employees
small (1-50)
Products
Genetically encoded bacterial injection–derived intracellular delivery platform
A platform produced by expressing a suite of genes in a microbial host to self-assemble delivery vehicles capable of delivering protein and peptide payloads into the cytosol of target cells.
Genetically encoded bacterial injection–derived intracellular delivery platform
A platform produced by expressing a suite of genes in a microbial host to self-assemble delivery vehicles capable of delivering protein and peptide payloads into the cytosol of target cells.
Services
Research and development of genetically encoded delivery systems for targeted cytosolic delivery of protein and peptide therapeutics.
Research and development of genetically encoded delivery systems for targeted cytosolic delivery of protein and peptide therapeutics.
Expertise Areas
- Intracellular biologic delivery
- Synthetic biology platform engineering
- Biomanufacturing via microbial fermentation
- Payload and targeting-domain engineering
Key Technologies
- Synthetic biology
- Genetically encoded delivery systems
- Bacterial injection–derived nanomachines
- Microbial fermentation for biologic production
News & Updates
Company featured in an article on engineering bacterial nanomachines into a therapeutic modality for targeted intracellular protein delivery.
Announcement of seasoned biotherapeutics leader joining as CEO to advance the intracellular delivery platform.
Raised £10M in a financing round co-led by multiple investors with participation from a corporate investor; announcement highlighted to support platform development.
Raised further seed financing to develop the biologic delivery platform.
Selected as the winner of a competitive accelerator programme for early-stage life sciences companies.
Recognized for innovation at an early-stage investor showcase event.
Company featured in an article on engineering bacterial nanomachines into a therapeutic modality for targeted intracellular protein delivery.
Announcement of seasoned biotherapeutics leader joining as CEO to advance the intracellular delivery platform.
Raised £10M in a financing round co-led by multiple investors with participation from a corporate investor; announcement highlighted to support platform development.
Raised further seed financing to develop the biologic delivery platform.
Selected as the winner of a competitive accelerator programme for early-stage life sciences companies.
Recognized for innovation at an early-stage investor showcase event.